Pharmaceutical giant GSK has reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed ...

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug.

GSK has struck a $2.2 billion agreement to settle the vast majority of U.S. lawsuits filed against it over claims its Zantac heartburn remedy causes cancer. The British drugmaker’s settlement ...

A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend itself from allegations that its Zantac drug caused cancer in patients. The three-day hearing ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.

GSK to pay $70 million to settle whistleblower lawsuit Pfizer and Sanofi also settling Zantac cases Boehringer Ingelheim faces trial, denies wrongdoing Oct 9 (Reuters) - GSK (GSK.L), opens new tab ...

The pharmaceutical giant reported a drop in profit due to charges related to the Zantac lawsuits but has reaffirmed guidance ...

Zantac’s manufacturers were on a roll. Their defense had exacted a spate of favorable decisions and jury verdicts. Yet, on October 9, Glaxo Smith Kline (GSK) suddenly settled 93% of the remaining ...

GSK to pay $2.2 billion to settle 93% of Zantac-related lawsuits. GSK targets £38 billion in sales by 2031, but market estimates fall short at £35.7 billion These cases account for 93% of the ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

The FTSE 100 index is set to remain under pressure, having fallen by 0.8% in yesterday’s session. Futures trading is pointing ...